Combining Biologic Agents
Studies of bevacizumab plus trastuzumab have produced
response rates with low-grade side effects. Studies are under
way to further examine that combination, as well as paclitaxel
plus trastuzumab, paclitaxel plus lapatinib, and all three
in combination.